image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 24.23
0.331 %
$ 1.12 B
Market Cap
-10.82
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PCRX stock under the worst case scenario is HIDDEN Compared to the current market price of 24.2 USD, Pacira BioSciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PCRX stock under the base case scenario is HIDDEN Compared to the current market price of 24.2 USD, Pacira BioSciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one PCRX stock under the best case scenario is HIDDEN Compared to the current market price of 24.2 USD, Pacira BioSciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PCRX

image
$28.0$28.0$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.0$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
701 M REVENUE
3.85%
-73.4 M OPERATING INCOME
-83.69%
-99.6 M NET INCOME
-237.30%
189 M OPERATING CASH FLOW
22.46%
-83.3 M INVESTING CASH FLOW
-107.40%
17.4 M FINANCING CASH FLOW
109.49%
169 M REVENUE
-9.79%
1.99 M OPERATING INCOME
-91.94%
4.81 M NET INCOME
-70.00%
35.5 M OPERATING CASH FLOW
7.02%
-25.6 M INVESTING CASH FLOW
-6864.40%
-2.99 M FINANCING CASH FLOW
-53.15%
Balance Sheet Pacira BioSciences, Inc.
image
Current Assets 745 M
Cash & Short-Term Investments 485 M
Receivables 113 M
Other Current Assets 147 M
Non-Current Assets 808 M
Long-Term Investments 0
PP&E 216 M
Other Non-Current Assets 592 M
31.19 %7.29 %9.48 %13.93 %38.11 %Total Assets$1.6b
Current Liabilities 310 M
Accounts Payable 19.1 M
Short-Term Debt 211 M
Other Current Liabilities 80.1 M
Non-Current Liabilities 465 M
Long-Term Debt 428 M
Other Non-Current Liabilities 37.1 M
27.18 %10.34 %55.24 %4.78 %Total Liabilities$775.2m
EFFICIENCY
Earnings Waterfall Pacira BioSciences, Inc.
image
Revenue 701 M
Cost Of Revenue 170 M
Gross Profit 531 M
Operating Expenses 604 M
Operating Income -73.4 M
Other Expenses 26.2 M
Net Income -99.6 M
800m800m700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)701m(170m)531m(604m)(73m)(26m)(100m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
75.69% GROSS MARGIN
75.69%
-10.47% OPERATING MARGIN
-10.47%
-14.20% NET MARGIN
-14.20%
-12.79% ROE
-12.79%
-6.41% ROA
-6.41%
-7.96% ROIC
-7.96%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pacira BioSciences, Inc.
image
180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m00(20m)(20m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -99.6 M
Depreciation & Amortization 78.8 M
Capital Expenditures -10.6 M
Stock-Based Compensation 51.2 M
Change in Working Capital 0
Others 157 M
Free Cash Flow 179 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pacira BioSciences, Inc.
image
Wall Street analysts predict an average 1-year price target for PCRX of $27.4 , with forecasts ranging from a low of $8 to a high of $57 .
PCRX Lowest Price Target Wall Street Target
8 USD -66.98%
PCRX Average Price Target Wall Street Target
27.4 USD 13.20%
PCRX Highest Price Target Wall Street Target
57 USD 135.25%
Price
Max Price Target
Min Price Target
Average Price Target
6060555550504545404035353030252520201515101055Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Pacira BioSciences, Inc.
image
Sold
0-3 MONTHS
523 K USD 2
3-6 MONTHS
16.2 K USD 1
6-9 MONTHS
9.88 K USD 1
9-12 MONTHS
105 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
216 K USD 5
9-12 MONTHS
7. News
Is the Options Market Predicting a Spike in Pacira BioSciences Stock? Investors need to pay close attention to PCRX stock based on the movements in the options market lately. zacks.com - 6 days ago
PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Pacira BioSciences, Inc. (NASDAQ:PCRX) on behalf of long-term stockholders following a class action complaint that was filed against Pacira on June 16, 2025 with a Class Period from August 2, 2023 – August 8, 2024. Our investigation concerns whether the board of directors of Pacira have breached their fiduciary duties to the company. globenewswire.com - 6 days ago
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRA). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRX. accessnewswire.com - 2 weeks ago
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on June 3, 2025 to 19 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval. globenewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRA). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRX. accessnewswire.com - 4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRA). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRA. accessnewswire.com - 1 month ago
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: globenewswire.com - 1 month ago
Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation SAN DIEGO , May 13, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX). Investors who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) prior to August 2023 and continue to hold any of those NASDAQ: PCRX shares also have certain options and contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. prnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRA). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PCRA. accessnewswire.com - 1 month ago
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth. zacks.com - 1 month ago
Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Jonathan Slonin - Chief Medical Officer Shawn Cross - Chief Financial Officer Brendan Teehan - Chief Commercial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Gary Nachman - Raymond James Hardik Parikh - JPMorgan Serge Belanger - Needham Operator Good day, and thank you for standing by. Welcome to the First Quarter 2025 Pacira BioSciences Earnings Conference Call. seekingalpha.com - 1 month ago
Pacira (PCRX) Q1 Earnings Surpass Estimates Pacira (PCRX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.62 per share a year ago. zacks.com - 1 month ago
8. Profile Summary

Pacira BioSciences, Inc. PCRX

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.12 B
Dividend Yield 0.00%
Description Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Contact 5401 West Kennedy Boulevard, Tampa, FL, 33609 https://www.pacira.com
IPO Date Feb. 3, 2011
Employees 788
Officers Ms. Susan Mesco Head of Investor Relations Ms. Lauren Bullaro Riker Principal Accounting Officer & Senior Vice President of Finance Mr. Charles A. Reinhart III, CPA, M.B.A. Executive Officer Mr. Anthony Molloy III, Esq. Chief Legal & Compliance Officer Mr. Christopher C. Young Chief Manufacturing Officer Ms. Kristen Williams Esq., J.D. Chief Administrative Officer & Secretary Mr. David M. Stack Advisor Dr. Jonathan Slonin M.D. Chief Medical Officer Mr. Frank D. Lee Chief Executive Officer & Director Mr. Shawn M. Cross Chief Financial Officer